1st International Conference on Artificial Intelligence in Oncology 2025 (Hybrid Mode)
Organized by Faculty of Science and Technology in collaboration with Washington University of Science and Technology, USA. & Research Cell, Vishwakarma University, Pune.
Date - 26th February 2025
Location : Vishwakarma University, Pune, Maharashtra, India
This track focuses on the intersection of artificial intelligence (AI) and the foundational principles of oncology. It aims to explore how AI technologies can enhance the understanding of cancer biology, pathophysiology, and fundamental mechanisms of tumorigenesis. As AI continues to play a transformative role in cancer research, this track will highlight AI’s contributions to unraveling the complexity of cancer biology and improving our understanding of tumor development, progression, and heterogeneity. It will also examine how AI tools are revolutionizing traditional approaches in cancer research, enabling breakthroughs in basic science that can directly impact clinical applications and therapeutic innovations.
This track will focus on the transformative role of Artificial Intelligence (AI) in public health, particularly in the prevention, early detection, and management of cancer. The intersection of AI with public health strategies offers vast potential to improve cancer screening, prevention programs, and overall healthcare systems, particularly in resource-limited settings. This track will explore how AI technologies can enhance population-based cancer control, improve the efficiency and accessibility of healthcare services, and reduce cancer-related disparities, ultimately improving global health outcomes.
Solid malignancies, which include cancers such as breast, lung, colorectal, prostate, and many others, remain among the leading causes of cancer-related morbidity and mortality worldwide. The application of Artificial Intelligence (AI) in these cancers offers immense potential for improving early detection, enhancing diagnostic accuracy, optimizing treatment strategies, and advancing personalized medicine. This track will explore how AI is being integrated into the management of solid tumors, with a particular focus on its role in diagnostics, treatment decision-making, predictive modeling, and therapeutic developments.
Hematological malignancies, including leukemia, lymphoma, and myeloma, represent a unique class of cancers that often present with complex diagnostic and therapeutic challenges. The integration of Artificial Intelligence (AI) in hematology offers significant potential to revolutionize how these diseases are diagnosed, treated, and managed. AI technologies are being leveraged to improve early detection, personalize treatment plans, predict treatment responses, and monitor disease progression in hematological cancers. This track will focus on the applications of AI in hematological malignancies, with an emphasis on clinical diagnostics, genomic profiling, treatment decision-making, and clinical trial optimization.
The landscape of oncology is rapidly evolving with the integration of Artificial Intelligence (AI) in areas that were once considered niche or complex. This track will focus on the "special topics" in oncology where AI is making a significant impact but may not yet be widely discussed in mainstream oncology conferences. These include areas such as rare cancers, immunotherapy, cancer prevention, AI in the palliative care setting, AI-driven healthcare optimization, and novel AI applications in multi-disciplinary approaches to cancer treatment. By bringing together multidisciplinary experts from AI, oncology, and healthcare, this track aims to explore the emerging opportunities and challenges that AI presents in these specialized areas of cancer research and treatment. The goal is to promote innovation, foster collaboration, and encourage the development of AI-driven solutions that address the unique needs of these specific areas in oncology.
Prospective authors are invited to submit full-length original research papers. While submitting a manuscript to ICAIO 2025, the authors acknowledge that no paper substantially similar in content has been or will be submitted to another journal, conference or workshop during the review period. In such a case the paper will be rejected without review. Papers must be electronically submitted before the deadline expires without exception through the submission link given.
The paper must not exceed 12 pages in length (including all text, figures, and references). The manuscript must be submitted in word/pdf format only and the file size of the manuscript should not exceed 10 MB.
ICAIO 2025 follows a single-blind review process. Hence, the authors must NOT remove the names and affiliations of authors from the paper.
Use a proper tool to convert the resulting source into a pdf document that has only scalable fonts with all fonts embedded.
The images embedded in the paper must not contain transparent pixels (i.e., an alpha-channel of a transparent color) since this could lead to problems when displaying or printing the pdf.
The pdf manuscript must not have Adobe Document Protection or Document Security enabled.
Authors must use the manuscript template specified here. The LaTeX and Word templates can be downloaded from the following links:
https://www.springer.com/gp/authors-editors/conference-proceedings/conference-proceedings-guidelines